Turmeric: Bridging Traditional Medicine and Contemporary Evidence in Therapeutic Applications

Abstract

Turmeric, the dried rhizome of Curcuma longa L., occupies an unusual position in therapeutic research. It has been used for centuries in Ayurveda and other Asian medical traditions, and it is now among the most intensively investigated botanicals in biomedical science, yet the translation from traditional practice to clinically dependable therapy remains uncertain. This critical narrative review examines how faithfully contemporary research has tested traditional uses of turmeric, how pharmacokinetic and mechanistic evidence shapes the interpretation of clinical findings, and where the balance of benefit and risk currently lies. Literature was identified through structured searches of open bibliographic and biomedical databases, a clinical trial registry, a regional scholarly index and authoritative institutional sources, supplemented by citation tracking, and was appraised qualitatively for design, test-article characterisation, exposure measurement, consistency and integrity. The synthesis indicates that most clinical trials have evaluated purified curcuminoid extracts or bioavailability-enhanced formulations rather than the whole-rhizome and food-matrix preparations described in traditional sources, so that clinical evidence speaks more directly to modern products than to traditional practice. The evidence is strongest for modest short-term relief of osteoarthritis pain, and an active-comparator trial supports benefit in functional dyspepsia, the indication closest to accepted traditional use. Findings for ulcerative colitis, glycaemic and lipid markers, depressive symptoms and hepatic enzymes are encouraging but rest on small, heterogeneous and geographically concentrated trials with low certainty, whereas trials in cognition and oncology remain inconsistent. Mechanistic interpretation is complicated by very low systemic concentrations of unconjugated curcumin, assay interference and chemical instability. Concentrated and bioavailability-enhanced products have been associated with idiosyncratic liver injury in which genetic susceptibility appears to play a part, while adulteration with lead chromate in parts of South Asia and variable product quality pose further substantive concerns. Bridging traditional knowledge and contemporary evidence therefore requires chemically characterised test articles, pharmacokinetically informed dosing, clinically meaningful endpoints, adequately powered trials in diverse populations and integrated pharmacovigilance. Turmeric is best regarded as a source of plausible but incompletely substantiated therapeutic hypotheses rather than as a validated remedy.